<DOC>
	<DOCNO>NCT00184366</DOCNO>
	<brief_summary>The main objective project : - To classify patient suffer plaque psoriasis respond give treatment ( efalizumab ) base upon reduction Psoriasis Area severity Index ( PASI ) , Psoriasis Disability Index 8PDI ) dermatology Life Quality Index 8 DLQI ) - To characterize patient suffer plaque psoriasis respond respond subcutaneous administrate efalizumab .</brief_summary>
	<brief_title>Classification Characterization Patients Treated With Efalizumab Plaque Psoriasis</brief_title>
	<detailed_description>This investigator initiate , prospective , longitudinal , observation study . Before start treatment efalizumab record factor demographic data , type psoriasis , previous treatment , diseases etc . We follow patient classify responder non-responders . We hope find 4-5 factor use later predict response drug .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>moderate severe plaque psoriasis six month eligible efalizumab treatment accord current Norwegian guideline Pregnant breastfeed patient Patients history uncontrolled bacterial , viral , fungal atypical mycobacterial infection . Patients suffer HIV , Hepatitis B C , active tuberculosis , hepatic cirrhosis hospital admission cardiac disease , stroke pulmonary disease within last year . Patients history cancer precede 5 year , include lymphoproliferative disorder . patient history fully resolve basal cell squamous cell skin cancer may enrol . Patients impaired renal hepatic function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>drug therapy</keyword>
	<keyword>efalizumab</keyword>
</DOC>